What do systematic reviews say?

38% SDF + potassium iodide solution (applied annually) vs Tricalcium silicate (TCS) paste (applied twice daily)

For early enamel lesions, annual SDF+KI was significantly LESS effective than twice-daily tricalcium silicate paste (54.8% vs 100% arrested; p<0.001; ungraded).

• A systematic review on the effect of silver diamine fluoride for management of dental caries in permanent teeth. 2023 All outcomes

  24 months · Outpatient clinic · Hamdi 2022 (early enamel lesions, Egypt)
  Proportion of lesions arrested (%) 54.8
  1 study · 45 participants
  GRADE not reported

Cell salvage vs no cell salvage

• Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery 2023 · Cochrane Headline outcomes only
  0.82 [0.38, 1.76]
  1 study · 1349 participants
  Low

Cell salvage vs no cell salvage

• Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 27 participants
  Low

Cell salvage vs no cell salvage

The review found no eligible studies for this question.

• Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Cell salvage vs no cell salvage

The review found no eligible studies for this question.

• Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Cell salvage vs no cell salvage

The review found no eligible studies for this question.

• Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Cell salvage vs no cell salvage

The review found no eligible studies for this question.

• Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Cell salvage vs no cell salvage

The review found no eligible studies for this question.

• Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

It is very uncertain whether mepolizumab 10 mg/kg changes histological improvement at 12 weeks (dichotomous) compared with mepolizumab 0.55 mg/kg (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 1.19 [0.37, 3.77]
  1 study · 39 participants
  Very low

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 0.63 [0.12, 3.38]
  1 study · 39 participants
  Very low

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

It is very uncertain whether mepolizumab 2.5 mg/kg changes histological improvement at 12 weeks (dichotomous) compared with mepolizumab 0.55 mg/kg (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 2.14 [0.79, 5.79]
  1 study · 39 participants
  Very low

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found